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The ability to adjust substrate oxidation according to nutrient availability has been termed 
‘metabolic flexibility’ and is a critical factor in overall metabolic health.   In respect to fatty acid 
oxidation (FAO) metabolic flexibility appears to be compromised with severe obesity (BMI > 
40kg/m
2
). When given a high-fat diet, healthy lean individuals increase their FAO, which is 
accompanied by increased expression of lipid-oxidizing genes. We observed an impairment in 
the ability to increase FAO in response to a high-fat diet in the skeletal muscle of obese 
individuals, which was accompanied by little or no change in the transcriptional upregulation of 
genes involved in FAO.  These data indicate a differential response to lipid oversupply with 
obesity which could contribute to positive lipid balance and weight gain.      
The molecular mechanisms contributing to this metabolic inflexibility with severe obesity 
are not evident. Acute epigenetic modifications of the genome, such as DNA methylation and 
histone acetylation, may provide a connection between nutritional factors, gene expression, and 
metabolic health. The purpose of the present study was therefore to determine if the expression 
of genes linked with FAO differed in a manner indicative of a lack of metabolic flexibility with 
 
 
 
 
obesity and to what extent the differential responses to lipid oversupply were linked with the 
chromatin environment and/or the methylation signature of these genes.   
By utilizing human skeletal muscle cultures (HSkMC) we were able to study the 
molecular adaptations to a lipid stimulus in the skeletal muscle of lean and obese humans.  The 
main findings were that: 1) the coordinated activation of genes linked with FAO among lean 
individuals in response to lipid oversupply is largely absent with obesity as evidenced by a 
blunted upregulation of several vital transcriptional regulators and 2) that changes in CpG 
methylation, increased histone acetylation, and transcription factor binding accompanied this 
response, suggesting that acute epigenetic modifications play a role in the lipid-induced 
upregulation of these genes.  These data provide the novel information that with severe obesity 
the metabolic inflexibility evident in response to lipid exposure may be linked with an inability 
to upregulate transcriptional regulators caused by differential epigenetic modifications.  
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CHAPTER 1: LITERATURE REVIEW 
PREVALENCE AND IMPACT OF SEVERE OBESITY 
In recent decades, the steady increase in the prevalence of obesity across all sex and age 
groups was significant (1). Some reports indicate that the increase in prevalence of obesity over 
the last decade has slowed, however as of 2008 32.2% of US adults are class I obese (BMI ≥ 30 
kg/m
2), 14.3% are class II obese (BMI ≥ 35 kg/m2), and 5.6% are class III obese (BMI ≥ 40 
kg/m
2), which is also referred to as “severely” or “extremely” obese (1, 2). When the prevalence 
trends for the higher classes of obesity are examined, it is clear that the prevalence of extreme 
obesity is increasing at alarming rates. According to national Behavioral Risk Factor Survey 
(BRFS) results, from 2000 to 2005 the prevalence of BMI ≥ 40 kg/m2 increased by 52%, while 
the prevalence of BMI ≥ 50 kg/m2 increased 75% (3).  
The increase in prevalence of extreme cases of obesity is associated with increased health 
care economic burden. This economic burden is disproportionately large for the most obese. For 
example, compared to an individual with a healthy weight status (BMI 18.5-24.9 kg/m
2
), 
individuals with a BMI between 35-40 kg/m
2
 spend 50% more, while individuals with a BMI 
greater than 40 kg/m
2
 doubled health care spending relative to an individual with a healthy 
weight status (4). Increased health care spending is a combination of more expensive office and 
emergency department visits as well as prescription medication costs. For example, medical 
treatment of extremely obese individuals often requires specialized equipment, supplies, and 
additional support staff (5).  
In addition to increased economic burden, it is well known that severe obesity is 
associated with an increased mortality rate and a variety of chronic diseases including 
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cardiovascular and metabolic diseases (i.e. insulin resistance, type 2 diabetes, etc.) (2). There is 
accumulating evidence that these metabolic diseases are associated with a defect in the ability of 
skeletal muscle to oxidize lipids (6) and an inability to adjust substrate oxidation according to 
nutrient availability, which has been termed ‘metabolic flexibility’ and is a critical factor in 
overall metabolic health (7).  
METABOLIC INFLEXIBILITY WITH SEVERE OBESITY 
In respect to fatty acid oxidation (FAO) metabolic flexibility appears to be compromised 
with obesity.  For example, several studies have reported an impairment in the ability to increase 
FAO in response to a 3-5d high-fat diet in the skeletal muscle of obese individuals (8, 9); this 
phenotype was also apparent with lipid incubation in primary human skeletal muscle cells raised 
in culture (HSkMC) (10). When given a high-fat diet, healthy lean individuals increase their 
FAO (9, 11), which is accompanied by increased expression of mitochondrial and lipid-oxidizing 
genes (e.g. peroxisome proliferator-activated receptor (PPAR)α and PPARγ coactivator-1α 
(PGC-1α)) (8, 10-14), while a high fat diet resulted in little to no change in the expression of 
these genes in obese subjects (8). These data indicate a differential response to lipid oversupply 
with obesity which likely contributes to positive lipid balance, ectopic lipid accumulation, 
intramuscular lipid accumulation associated with insulin resistance, weight gain, and weight 
regain after weight loss (15, 16).  
The molecular mechanisms contributing to this metabolic inflexibility with severe obesity, 
however, are not evident. Epigenetic modifications provide a potential molecular basis for the 
interaction between genetic and environmental factors and have been implicated in metabolic 
diseases, stroke, and cardiovascular disease (17-20). Acute epigenetic modifications of the 
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genome, such as DNA methylation and histone acetylation, may provide a connection between 
nutritional factors, gene expression, and metabolic health and could help explain the differential 
responses in the coordinated gene expression in the skeletal muscle of lean vs. severely obese 
individuals. DNA methylation is generally accepted to regulate gene transcription by directly 
impeding the binding of transcriptional factors to their target sites and through the recruitment of 
methyl-binding proteins (21). Histone acetylation affects both chromatin structure as well as the 
interaction of transcription-regulatory proteins with target DNA in chromatin (22). For example, 
an increase in the acetyl groups on histones will result in an open chromatin structure to facilitate 
accessibility of transcriptional machinery to DNA templates in chromatin, in turn increasing the 
expression of a gene. There is a large body of evidence on the functional significance of both 
histone acetylation and DNA methylation levels and their correlation with gene expression as 
well as their importance in integrating environmental stimuli, such as diet, in the control of gene 
expression (21, 22). For example, with a 5 d high fat diet Jacobsen et al. (23) observed 
widespread DNA methylation changes in human skeletal muscle and Barres et al. (17) reported 
increased non-CpG methylation of the PGC-1α promoter region in HSkMC with a 48hr 500µM 
palmitate incubation. However, these studies (9,10,11) examined skeletal muscle from lean 
individuals; it is not evident if differences in DNA methylation patterns may explain, at least in 
part, the divergent  responses to lipid of genes involved with mitochondrial biogenesis and FAO 
in the skeletal muscle of obese vs. lean individuals (3).  
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ARE EPIGENETIC MODIFICATIONS CONTRIBUTING TO METABOLIC 
INFLEXIBILITY?  
This dissertation focused on determining whether the differential responses to lipid 
oversupply of genes linked with mitochondrial content and FAO with severe obesity are linked 
with epigenetic modifications, including DNA methylation and histone acetylation, in a manner 
indicative of a lack of metabolic flexibility. The nuclear respiratory factors (NRFs) and 
peroxisome proliferator-activated receptors (PPARs) and are provocative candidates for 
explaining the metabolic inflexibility in response to lipid oversupply with obesity as they 
activate gene expression programs critical to mitochondrial function and FAO (24-27).  
The NRFs are required for the expression of the respiratory apparatus in mammalian cells 
and vital for mitochondrial biogenesis and maintenance as indicated by early mortality of NRF-
1-null embryos (24). The PPARs are ligand-activated transcription factors that play essential 
roles in lipid homeostasis by modulating the expression of genes that regulate fatty acid 
catabolism. One particularly attractive PPAR-regulated candidate is carnitine 
palmitoyltransferase (CPT1) which mediates the transfer of long chain fatty acids across the 
outer mitochondrial membrane which is a rate-limiting step in FAO (28). The activity of the 
muscle-type CPT1 (encoded by the CPT1B gene) is reduced in skeletal muscle with obesity, 
contributing to a decrease in FAO (29). In relation to metabolic flexibility, in the skeletal muscle 
of lean subjects a high fat diet increased the expression of CTP1B and the peroxisome 
proliferator-activated receptors (PPARs) which are upstream regulators of CPT1B expression (8).  
Conversely, a high fat diet resulted in little to no change in the expression of these genes in the 
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skeletal muscle of severely obese subjects indicating a differential response to lipid oversupply 
with severe obesity (8).   
Therefore, the specific purpose of this dissertation was to determine if the expression of 
PPAR- and/or NRF-regulated genes linked with FAO and mitochondrial content differed in a 
manner indicative of a lack of metabolic flexibility with severe obesity and to what extent the 
differential responses to lipid oversupply were linked with the chromatin environment and/or the 
methylation signature of these genes. By utilizing HSkMC we were able to study the molecular 
adaptations to a lipid stimulus in an environment void of in-vivo hormonal and neural stimuli and 
thus intrinsic to skeletal muscle itself.  
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CHAPTER 2: SKELETAL MUSCLE FROM THE SEVERELY OBESE IS 
METABOLICALLY INFLEXIBLE IN TERMS OF GENE REGULATION AND DNA 
METHYLATION IN RESPONSE TO LIPID OVERSUPPLY  
ABSTRACT 
Objective: The skeletal muscle of severely obese individuals (BMI ≥ 40 kg/m2) is characterized 
by a failure to upregulate fatty acid oxidation (FAO) in response to increased lipid availability, 
which is associated with a failure to coordinately upregulate genes involved in FAO.  The 
present study was undertaken to determine if the differential responses to lipid oversupply of 
genes linked with mitochondrial content and FAO with severe obesity are linked with the 
methylation signatures of these genes.   
Research design and methods: RNA and DNA were isolated in human skeletal muscle cell 
cultures from 9 lean and 10 severely obese women following lipid incubation. mRNA content 
was measured using RT-PCR. Methylation was quantified using the Illumina 
HumanMethylation450 BeadChip. 
Results: The upregulation of several vital transcriptional regulators of FAO and mitochondrial 
content were depressed in the severely obese compared to their lean counterparts in response to 
lipid oversupply and there is evidence that the expression of PPARδ, which regulates a broad 
transcriptional program related to energy metabolism, is controlled by changes in CpG 
methylation.  
Conclusions: With severe obesity, the metabolic inflexibility evident with lipid exposure is 
linked with an inability to upregulate several transcriptional regulators and methylation may play 
a role in this transcriptional regulation.  
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INTRODUCTION 
The ability to adjust substrate oxidation according to nutrient availability has been termed 
‘metabolic flexibility’ and is a critical factor in overall metabolic health (7).  In respect to fatty 
acid oxidation (FAO), metabolic flexibility appears to be compromised with obesity.  For 
example, several studies have reported an impairment in the ability to increase FAO in response 
to a 3-5d high-fat diet in the skeletal muscle of obese individuals (8, 9); this phenotype was also 
apparent with lipid incubation in primary human skeletal muscle cells raised in culture (HSkMC) 
(10).  Additionally, in the skeletal muscle of lean subjects a high-fat diet increased the expression 
of genes involved in mitochondrial biogenesis and FAO (i.e. peroxisome proliferator-activated 
receptor (PPAR)α and PPARγ coactivator-1α (PGC-1α)) (8, 10-14), while a high-fat diet resulted 
in little to no change in the expression of these genes in obese subjects (8).   These data indicate 
a differential response to lipid oversupply with obesity which could contribute to positive lipid 
balance and ectopic lipid accumulation (15, 16, 30, 31).     
Acute epigenetic modifications of the genome, such as DNA methylation, may provide a 
connection between nutritional factors, gene expression, and metabolic health.  For example, 
with a 5d high-fat diet Jacobsen et al. (23) observed widespread DNA methylation changes in 
human skeletal muscle and Barres et al. (17) reported increased non-CpG methylation of the 
PGC-1α promoter region in HSkMC with a 48hr 500µM palmitate incubation.  However, these 
studies (17, 23) examined skeletal muscle from lean individuals; it is not evident if differences in 
DNA methylation patterns may explain, at least in part, the divergent responses to lipid of genes 
involved with mitochondrial biogenesis and FAO in the skeletal muscle of obese vs. lean 
individuals.  The purpose of the present study was therefore to determine if the differential 
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responses to lipid oversupply of genes linked with mitochondrial content and FAO with obesity 
are linked with the methylation signatures of these genes.  By utilizing HSkMC we are able to 
study the molecular adaptations to a lipid stimulus in an environment void of in-vivo hormonal 
and neural stimuli and thus intrinsic to skeletal muscle itself. 
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RESEARCH DESIGN AND METHODS 
Study Design 
The design of the study was to compare the responses of genes linked with FAO and 
mitochondrial biogenesis to lipid oversupply in lean vs. obese subjects.  Skeletal muscle was 
obtained from the vastus lateralis and used to derive primary human skeletal muscle cell cultures 
(HSkMC).  After differentiation into myotubes, HSkMC were incubated in a physiologically 
relevant lipid mixture (32) (250µM oleate:palmitate) for 48hr and mRNA content and DNA 
methylation determined. The mRNA content of the peroxisome proliferator-activated receptors 
(PPARs) and nuclear respiratory factors (NRFs) were selected to be analyzed because of their 
importance in activating gene expression programs critical to mitochondrial function and FAO 
(24-27). Additionally, downstream PPAR and NRF-regulated genes that play vital roles in 
mitochondrial content and FAO were analyzed as well.  
Materials 
All chemical reagents and substrates were purchased from Sigma (St. Louis, MO, USA) 
unless otherwise stated. Dulbecco’s Phosphate-Buffered Saline (DPBS), fetal bovine serum, 
heat-inactivated horse serum, gentamicin, 0.05% trypsin EDTA, and Hanks’s balanced salt 
solution were obtained from Invitrogen.  Growth media and differentiation media consisted of 
low glucose (5 mmol/L) Dulbecco’s Modified Eagles Medium from Invitrogen.  Type I collagen-
coated tissue culture plates were obtained from Becton Dickinson (Franklin Lakes, NJ, USA).  
PCR reagents were purchased from Applied Biosystems (Foster City, CA, USA).  
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Human Subjects 
Muscle biopsies were obtained using the percutaneous needle biopsy technique (33) 
under local anesthesia (0.01% lidocaine) from the vastus lateralis of 9 lean (BMI= 22.8 kg/m
2
 
±2.2; Age= 23.4yrs ±4.6) and 10 obese (Class II to III) (BMI= 41.3 kg/m
2
 ±4.9; Age= 
30.2yrs±8.3) Caucasian women.  Characteristics are presented in Table 1.  Participants were 
relatively young, free from overt disease, nonsmokers and not taking medications known to alter 
metabolism.  All procedures were approved by the East Carolina University Institutional Review 
Board.  
Primary HSkMC 
Satellite cells were isolated from ~50-100mg of fresh muscle tissue and cultured as 
previously described (34).  For experiments cells were sub-cultured into T-150 flasks and 10cm 
dishes.  Upon reaching ~80-90% confluence, differentiation was induced by switching the 
growth media to low-serum differentiation media containing 2% heat-inactivated horse serum, 
0.05 mg/ml fetuin, and 5 µg/ml gentamicin.  On day 5 of differentiation, myotubes were given 
fresh differentiation media supplemented with 1) 0.1% bovine serum albumin (BSA) + 1mM 
carnitine (CONTROL) or 2) 250µM oleate:palmitate (1:1 ratio) bound to 0.1% BSA + 1mM 
carnitine (LIPID) for a total incubation period of 48 hours.  Myotubes were harvested on day 
seven similar to previous work (35).  There were no obvious differences in the extent of 
differentiation or myotube morphology between lean and obese HSkMC.  
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RNA Isolation and mRNA quantification 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) with on-
column DNase digestion using the RNase-Free DNase Set (Qiagen, Valencia, CA) to remove 
residual DNA.  RNA was quantified using the NanoDrop 1000 Spectrophotometer Version 3.7.1 
from Thermoscientific (Wilmington, DE, USA) and concentration was determined by measuring 
the absorbance at 260nm.  2ug of RNA was reverse transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription Kit from Applied Biosystems (Foster City, CA, USA).  
PCR was performed in triplicate using the Applied Biosystems ABI 7900HT sequence detection 
instrument and software with Taqman Universal PCR Master Mix and TaqMan gene expression 
assays (Applied Biosystems, Foster City, California) in accordance with manufacturer’s 
instructions.  Using standard techniques, reactions were run with the following thermal cycling 
conditions: 50˚C for 2 min; 95˚C for 10 min; and 40 cycles of 95˚C for 15 s; followed by 60˚C 
for 1 min.  mRNA content was measured using the comparative Ct method with a multiplexed 
endogenous control (18S) and converted to a linear function by using a base 2 antilog 
transformation.  
DNA Isolation  
Cells were washed with DPBS and trypsinized with trypsin-EDTA (0.05% trypsin and 
0.25% EDTA). Total DNA (mitochondrial and nuclear) was extracted from cells using a 
QIAamp DNA mini kit (Qiagen, Valencia, CA), and total DNA quantified using the NanoDrop 
1000 Spectrophotometer Version 3.7.1 from Thermoscientific (Wilmington, DE, USA).  
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Bisulfite Conversion and DNA Methylation Profiling  
500ng of DNA was bisulfate converted using the EZ DNA Methylation Kit (Zymo 
Research, Orange, CA) following the manufacturer’s protocol, with the alternative incubation 
conditions recommended when using the Illumina Infunium Methylation Assay.  Genome-wide 
DNA methylation analysis was conducted on bisulfate treated DNA samples using the Illumina 
Infinium HumanMethylation 450K BeadChip, which allows the quantitative monitoring of 
485,764 cytosine positions (36).  12uL of each bisulfate-converted sample was amplified and 
fragmented, following the manufacturer’s protocol, hybridized to arrays in a balanced design and 
scanned on an Illumina iScan System.  Data were output and analyzed using Illumina’s Genome 
Studio software. 
Statistical analysis 
Statistical analyses were performed using PASW Statistics 19 Software (SPSS Inc., 
Chicago, IL, USA) on raw or log-transformed data.  Comparisons between HSkMC from lean 
and obese donors were performed with repeated measures ANOVA, with emphasis on a “weight 
status” (lean, severely obese) X “treatment” (control, lipid-treated) interaction indicating that 
lean and severely obese individuals responded differently to lipid oversupply.  All data met 
assumptions of sphericity and homogeneity of variance.  Data are presented as the mean ± SEM. 
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RESULTS 
Participant Characteristics 
Participant characteristics are presented in Table 1.  By design, the obese subjects were 
heavier and most had a body mass index (BMI) classified as Class III (severe) obesity (≥40 
kg/m
2
).  Fasting blood glucose, cholesterol, and triglyceride values did not differ between 
groups.  However fasting HDL values were significantly lower, while insulin and homeostatic 
model assessment values were significantly higher in the obese subjects.  Both groups consisted 
of relatively young individuals, however, the age of the obese group was higher compared to the 
lean group (P=0.05). 
Gene Expression 
Under the control condition (i.e. pre-lipid exposure), there were no differences between 
the groups in PPARα, NRF-1, and NRF-2 mRNA content; however, PPARδ mRNA content was 
significantly lower (P=0.04) in the obese individuals compared to the lean (Fig. 2.2).  In 
response to the  48h 1:1 oleate:palmitate lipid treatment, there were  significant (P≤0.05) 
interaction effects for PPARα, PPARδ, NRF-1, and NRF-2 where mRNA content was elevated in 
the lipid-treated state in HSkMC from the lean, but not obese subjects (Fig. 2.1 and 2.2).  There 
were no differences in the mRNA content between groups in either condition for PGC-1α, PGC-
1β, and peroxisome proliferator-activated receptor gamma coactivator-related protein 1 (PPRC1) 
(Fig. 2.1).  
In an effort to determine whether the differential expression of these transcriptional 
regulators had a downstream effect, four PPAR-responsive genes that play a vital role in FAO 
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were analyzed (Table 2.2) angiopoieten-like 4 (ANGPTL4), 2) citrate synthase (CS), 3) pyruvate 
dehydrogenase kinase 4 (PDK4), and 4) mitochondrial uncoupling protein 3 (UCP3).  There was 
a significant interaction effect for PDK4 (P≤0.05) with the lipid-induced change in mRNA being 
significantly lower (P≤0.05) in the HSkMC from the obese (20.4 ±3.8 fold increase) compared to 
the lean (42.0±8.1 fold increase) subjects (Fig. 2.3A).  Similarly, the lipid-induced increase in CS 
and UCP3 mRNA content in HSkMC from the obese (1.2 ±0.2 and 1.2±0.1 fold increase) 
compared to the lean (1.6±0.1 and 0.9±0.1 fold increase) exhibited a trend (P=0.1 and P=0.09) 
for being suppressed with obesity.  Six NRF regulated genes were analyzed (Table 2.2): 1) 
cytochrome c oxidase subunit VIc (COX6c), 2) cytochrome c (CYCS), 3) mitochondrial 
elongation factor G 1 (GFM1), 4) mitochondrial ribosomal protein L2 (MRPL2), 5) 
mitochondrial transcription factor A (TFAM), and 6) mitochondrial transcription factor B2 
(TFB2M).  The lipid-induced increase in CYCS mRNA content was significantly (P=0.05) lower 
in the obese (0.9±0.1 fold increase) compared to the lean (1.3±0.2 fold increase) subjects (Fig. 
2.3B).  
DNA Methylation 
Overall, DNA methylation was determined on 485,764 cytosine positions.   In terms of 
genes exhibiting differential responses with obesity (Fig. 2.2) within the PPARδ gene DNA 
methylation was determined in 23 sites (Fig. 2.4A), with nine cytosines being within 1000 base 
pairs (bp) of the transcription start site (TSS).  In response to the lipid oversupply, there were 
significant (P≤0.05) interaction effects for cytosines at positions 6 and 7 (-71 and -61bp relative 
to the TSS) in PPARδ where methylation increased in the lipid-treated state in HSkMC from the 
lean, but not obese subjects.  From baseline, lipid oversupply resulted in a significant (P≤0.05) 
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increase in the methylation of three cytosines (at positions 6, 7, and 23) in HSkMC from lean but 
not obese women (Fig. 2.4B and C).  Lipid oversupply resulted in a similar, significant (P≤0.05) 
increase in the methylation of the cytosine at position 14 (41,044bp relative to the TSS) in both 
the lean and obese subjects (Fig. 2.4B and C).  When the absolute methylation percentage of the 
PPARδ gene with lipid treatment was compared between the lean and obese subjects, lipid 
oversupply resulted in a significantly lower (P≤0.05) percentage of methylation among two 
cytosines at positions 6 and 7 in HSkMC from the obese compared to the lean (Fig. 2.5).  
Additionally, there was a trend for the methylation of two additional cytosines at positions 4 
(P=0.08) and 5 (P=0.06) (-78 and -75bp relative to the TSS) to be lower in the lean compared to 
the obese in the lipid-treated condition.  With lipid treatment methylation of the cytosine at 
position 6 (-71bp from TSS) significantly increased by an average of 1.5±0.6% in the lean and 
decreased an average of 0.6±0.3% in the obese, which was positively correlated (r=0.64, P=0.01) 
with the relative change in PPARδ mRNA content in response to lipid treatment (Fig. 2.6A).  
With lipid treatment the methylation of the cytosine at position 6 was 6.4±0.7% in the lean and 
4.3±0.3% in the obese (Table S2.1), which positively correlated (r=0.53, P=0.03) with PPARδ 
mRNA content measured in the lipid-treated condition (Fig. 2.6B).  Methylation did not change 
significantly in any of the other differentially expressed genes examined in this study.  
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 DISCUSSION 
With obesity, there are impairments in the ability to adjust substrate utilization to changes 
in substrate availability (37-39).  In respect to lipid metabolism, we reported that obese 
individuals lacked the ability to increase fat oxidation with either a high fat diet (9) or in HSkMC 
upon lipid incubation (10).   In the present study, we examined if the expression of genes linked 
with FAO and mitochondrial content also differed in a manner indicative of a lack of metabolic 
flexibility with obesity and if these differences in gene expression could be explained by 
methylation signatures.  The main findings were that: 1) the upregulation of several vital 
transcriptional regulators of FAO and mitochondrial content were depressed in the severely 
obese women compared to their lean counterparts in response to lipid oversupply and 2) that the 
expression of PPARδ, which regulates a broad transcriptional program related to energy 
metabolism, may be controlled by changes in CpG methylation.  These data provide the novel 
information that with severe obesity the metabolic inflexibility evident with lipid exposure may 
be linked with an inability to upregulate some transcriptional regulators via methylation.   
The peroxisome proliferator-activated receptors (PPARs) and nuclear respiratory factors 
(NRFs) are provocative candidates for explaining the metabolic inflexibility in response to lipid 
oversupply with obesity as they activate gene expression programs critical to mitochondrial 
function and FAO (24-27).  The PPARs are ligand-activated transcription factors that play 
essential roles in lipid homeostasis by modulating the expression of genes that regulate fatty acid 
catabolism.  There are three PPAR subtypes: 1) PPARα, which mediates lipid-induced activation 
of FAO genes and is expressed predominately in tissues that are characterized by high rates of 
FAO (ie. liver, heart, muscle, kidney); 2) PPARγ, which is highly enriched in adipocytes and 
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macrophages and is involved in adipocyte differentiation, lipid storage, and glucose homeostasis; 
and 3) PPARδ, which is ubiquitously expressed and has the least defined function, but has 
recently been characterized as being highly expressed in skeletal muscle and playing a lipid-
metabolizing role similar to PPARα (25, 26, 40).  Their critical role in energy homeostasis is 
supported by the observation that PPARα knockout mice exhibit a dramatic inhibition of fatty 
acid uptake and oxidation, abnormal accumulation of lipids in oxidative tissues, and a failure to 
induce beta-oxidation in response to physiological challenges such as a high-fat diet (35).  The 
NRFs are required for the expression of the respiratory apparatus in mammalian cells and vital 
for mitochondrial biogenesis and maintenance, as indicated by early mortality of NRF-1-null 
embryos (24).  In the current study, broad transcriptional regulators, including PPARα, PPARδ, 
NRF-1, and NRF-2, exhibited similar patterns of increasing mRNA content with lipid exposure 
in the lean, but decreasing or not changing mRNA in HSkMC from the severely obese (Fig. 1).  
Additionally, several NRF- and PPAR-responsive genes including CYCS, CS, UCP3, and PDK4 
showed trends for being upregulated more robustly in HSkMC from lean but not obese subjects.  
We cannot discount the possibility that these findings may have been influenced by the time we 
chose to obtain the samples, i.e. that similar mRNA responses in lean and obese subjects could 
have occurred at earlier or later time points during lipid incubation.  However, the present data 
remain indicative of a coordinated lipid-induced activation of genes linked with FAO and 
mitochondrial content among lean individuals in response to lipid oversupply that is largely 
absent with obesity  
Of the PPAR-responsive genes that were differentially regulated by the 48hr lipid 
oversupply pyruvate dehydrogenase kinase 4 (PDK4) is of particular interest as it suppresses 
glucose and promotes fat oxidation in the presence of lipids (41).  We have previously shown 
 21 
 
that a high-fat diet increased PDK4 mRNA content in lean, but not obese individuals; in the 
current study utilizing HSkMC, the lipid-induced increase in PDK4 mRNA content in the lean 
was more than 2-fold greater than the response in the obese (42.0±8.1 vs. 20.4±3.8 fold increase) 
(Fig. 3).  Other data have reported a significant interaction effect in response to a high fat diet 
where the increase in PDK4 mRNA content was more pronounced in obese individuals relative 
to lean (42).  A possible reason for these divergent findings is that the current study utilized 
HSkMC from severely obese women (Class II to III) (BMI= 41.3 kg/m
2
 ±4.9), while the analysis 
in Bergouignan et al. (42) measured skeletal muscle mRNA content isolated from men and 
women with a lower mean BMI (35.1 kg/m
2
 ±4.1).  This suggests that the ability to adjust to 
substrate availability may depend on the level of excess adiposity (42), which is in agreement 
with other data indicating that disturbances in lipid metabolism are evident in the skeletal muscle 
of extremely obese, but not moderately obese individuals (43).  PDK4 protein content is 
primarily regulated via transcription (44); thus although PDK4 content was not determined, such 
a lack of metabolic flexibility could contribute to detrimental conditions such as positive fat 
balance (30), ectopic lipid accumulation (31), and weight gain (39).  
Epigenetic processes (ie. DNA methylation) may provide a mechanism for the regulation 
of gene expression in response to lipid and/or could help explain the differential responses in 
gene expression in the skeletal muscle of lean vs. severely obese individuals.  The extent to 
which methylation changed in response to lipid oversupply tended to be lower in the obese 
subjects (Fig. 4).  This finding is in accordance with previous work showing that individuals at a 
greater risk of developing metabolic disease tended to have a lower sensitivity to environmental 
challenges (ie. high-fat feeding) in terms of the ability to regulate changes in DNA methylation 
(45).  With lipid oversupply we observed significant increases in PPARδ methylation at two 
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cytosines positioned within 100bp of the TSS in the lean, however, there were no significant 
changes in the methylation status of these two cytosines in the obese (Fig. 4).  A cluster of 
cytosines -78 to -61bp relative to the TSS increased in the lean in response to lipid oversupply 
suggesting the increase in methylation was targeted to the promoter region of PPARδ (Fig. 4).  
Of the cytosines within the cluster, the central one (-71bp from the TSS at position 6) was highly 
related to PPARδ mRNA content (Fig. 6).  
DNA methylation is generally accepted to regulate gene transcription by directly 
impeding the binding of transcriptional factors to their target sites and through the recruitment of 
methyl-binding proteins (21).  However, our findings indicate a positive relationship between the 
extent of PPARδ promoter methylation and PPARδ mRNA content in response to lipid 
oversupply (Fig. 6).  In support of our findings, in human skeletal muscle Barres et al. (46) 
identified a subset of genes with positive relationships between gene expression and promoter 
methylation and suggested that DNA methylation at a transcriptional repressor binding site could 
subsequently induce gene expression.  Pipaon et al. (47) found that increased methylation of p73, 
a gene related to the p53 tumor suppressor protein, blocked the binding of the zinc finger 
transcription factor repressor protein ZEB in human fibroblasts, in turn promoting the expression 
of p73; treatment with an inhibitor of DNA methyltransferase significantly also reduced the 
expression levels of p73 (47).  Similarly, Ando et al.(48) found that demethylation of a repressor 
binding site elicited a concomitant decrease in gene expression (48).  Although speculative at 
this point, our findings indicate a potential mechanism regulating the lipid-induced increase in 
PPARδ gene expression in the lean could be the blockage of a repressive factor from binding to 
the PPARδ promoter via DNA methylation.  
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In the present study there were no baseline differences in PGC-1α and PDK4 mRNA 
content and promoter methylation between the lean and severely obese women which is 
inconsistent with a recent report (46) where mRNA content of PGC-1a was significantly lower 
and PDK4 mRNA content was significantly higher in muscle biopsies obtained from obese 
subjects.  A possible reason for these divergent findings is that the current study utilized 
HSkMC, where hormonal and/or neural input that could differ with obesity and potentially 
influence gene expression are eliminated.  In terms of promoter methylation, in Barres et al. (46) 
the majority of methylated cytosines in the PGC-1α and PDK4 promoter regions were found 
within non-CpG sites whereas the present study only examined CpG sites, which have been 
previously demonstrated to regulate gene expression (22).  Additionally, the composition of lipid 
incubation media has differed between studies; an increase in PGC-1a promoter methylation was 
evident with a 48hr 500µM palmitate incubation whereas we did not observed changes with a 
48hr 250µM 1:1 oleate:palmitate lipid mixture.  It is well-known that different fatty acids impart 
specific and unique effects, or even opposing actions, on cellular functions (32), which likely 
explains why findings differ between studies.  We chose to utilize the oleate:palmitate mixture as 
it more closely mimics physiological conditions (32). 
In summary, primary human skeletal muscle cell cultures (HSkMC) were utilized to 
study adaptations to a lipid stimulus in the skeletal muscle of lean and severely obese humans.  
Our findings indicate a coordinated lipid-induced activation of genes linked with FAO and 
mitochondrial content among lean individuals in response to lipid oversupply that is largely 
absent with obesity.  In HSkMC from severely obese individuals, PPARδ displayed differential 
methylation patterns in the promoter region compared to cells derived from lean subjects; 
changes in the methylation signature may thus play a role in controlling gene expression.  
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TABLES AND FIGURES 
Table 2.1. Subject characteristics. 
 Lean (n=12) Obese (n=10) 
Age (y) 23.4±1.5 30.2±2.6* 
Stature (cm) 164.7±1.8 165.5±2.2 
Mass (kg) 62.6±1.3 113.7±6.3* 
BMI (kg/m
2
) 22.8±0.7 41.3±1.5* 
Fasting glucose (mmol/L) 4.6±0.1 4.9±0.1 
Fasting insulin (uU/L) 4.3±1.2 17.3±5.0* 
HOMA-IR 0.9±0.3 3.8±1.1* 
Plasma cholesterol (mg/dl) 179±8.2 171±10.1 
Plasma triglycerides (mg/dl) 102±7.4 121±21.0 
HDL (mg/dl) 56±4.0 40±3.4* 
 
Results are expressed as mean±SEM 
*Significantly different (P < 0.05) from lean. 
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Table 2.2. Genes regulated by the NRFs and PPARs.   
 
 Response Element  
Gene NRF PPAR Description 
ANGTPL4  X angiopoietin-like 4 
CS  X citrate synthase 
PDK4  X pyruvate dehydrogenase kinase 4 
UCP3  X mitochondrial uncoupling protein 3 
COX6C X  cytochrome c oxidase subunit 6 C 
CYCS X  somatic cytochrome c 
GFM1 X  mitochondrial elongation factor G 1 
MRLP2 X  mitochondrial ribosomal protein L 2 
TFAM X  mitochondrial transcription factor A 
TFB2M X  mitochondrial transcription factor B 2 
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Figure 2.1. Relative change in mRNA content in response to 48hr 250µM oleate:palmitate 
treatment in cultured myotubes (HSkMC) from lean (open bars) and severely obese (solid bars) 
donors. Data are expressed as the fold change (lipid-treated divided by baseline) (mean± SEM). 
No change is a value of 1, which is represented by the dashed line, with values > 1.0 indicative 
of an increase in respective mRNA content with the lipid-treatment. *, Significant difference 
(P≤0.05) between lean and obese individuals.  
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Figure 2.2.  Effect of lipid oversupply (48hr 250µM oleate:palmitate treatment) on mRNA 
content of PPARδ in cultured myotubes (HSkMC) from lean (open bars) and severely obese 
(solid bars) donors. Data are expressed as mean±SEM. *, Significant difference (P≤0.05) 
between lean and obese individuals. Φ, Significant difference (P≤0.05) between control and 
lipid-treated.  
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Figure 2.3.  Relative change in the mRNA content of PPAR-regulated genes (A) and NRF-
regulated genes (B) in response to 48hr 250µM oleate:palmitate treatment in cultured myotubes 
(HSkMC) from lean (open bars) and severely obese (solid bars) donors. Data are expressed as 
the fold change (lipid-treated divided by baseline) (mean± SEM). No change is a value of 1, 
which is represented by the dashed line, with values > 1.0 indicative of an increase in respective 
mRNA content with the lipid-treatment. *, Significant difference (P≤0.05) between lean and 
obese individuals. #, Difference between lean and obese individuals approached significance 
(P≤0.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 34 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
  
PPAR Regulated Genes
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
 (
L
ip
id
-T
re
a
te
d
/C
o
n
tr
o
l)
0.0
0.5
1.0
1.5
2.0
15
30
45
60
75
90
105
Lean
Obese
*
A
N
G
P
T
L4 C
S
P
D
K
4
U
C
P
3
#
#
NRF Regulated Genes
m
R
N
A
 F
o
ld
 C
h
a
n
g
e
(L
ip
id
-T
re
a
te
d
/C
o
n
tr
o
l)
0.0
0.5
1.0
1.5
2.0
C
O
X
6C
C
Y
C
S
G
FM
1
M
R
P
L2
T
FA
M
T
FB
2M
*
 35 
 
Figure 2.4. PPARδ gene methylation. Visualization of the 23 measured CpG sites within the 
PPARδ gene (A). DNA methylation changes in response to lipid oversupply (methylation value 
in the lipid-treated condition minus the baseline methylation value) at each of the 23 measured 
CpG sites among the lean individuals (B) and the severely obese individuals (C). *, Significant 
difference (P≤0.05) between the baseline and lipid-treated condition. TSS is indicated by the 
arrow.  
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Figure 2.5. Methylation of 23 cytosines within the PPARδ gene in the lipid-treated condition. 
Data are presented as obese methylation values relative to lean  (the obese lipid-treated 
methylation value divided by the lean lipid-treated methylation) (mean± SEM). No  differences 
in the methylation of cytosines in the lipid-treated condition between lean and obese is a value of 
1, which is represented by the dashed line, with values < 1.0 indicative of lower methylation 
levels among the obese compared to the lean.*, Significant difference (P≤0.05) between lean and 
obese individuals. #, Difference between lean and obese individuals approached significance 
(P≤0.1).  
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Figure 2.6. The association of PPARδ methylation and PPARδ mRNA content. The change in 
methylation in response to lipid oversupply (methylation value in the lipid-treated condition 
minus the baseline methylation value) of the cytosine at position 6 was positively related to the 
relative change in PPARδ mRNA content (lipid-treated divided by baseline) (A). Methylation of 
the cytosine at position 6 in the lipid-treated condition was positively related to PPARδ mRNA 
content in the lipid-treated condition (B).    
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Supplementary Table 2.1. Baseline and lipid-treated methylation values for 23 CpG sites within 
the PPARδ gene. 
 
Lean vs. obese *P≤0.05 
Lean vs. obese #P≤0.10 
 
 
 
 
 
 
CHAPTER 3: EPIGENETIC MODIFICATIONS PLAY A ROLE IN THE 
DIFFERENTIAL TRANSCRIPTIONAL REGULATION OF CPT1B IN LEAN AND 
SEVERELY OBESE WOMEN IN RESPONSE TO LIPID OVERSUPPLY 
ABSTRACT 
The skeletal muscle of severely obese individuals cannot increase fatty acid oxidation 
(FAO) in response to dietary lipid, which is associated with a failure to coordinately upregulate 
genes involved in FAO, termed metabolic inflexibility.  While the molecular mechanisms 
contributing to this metabolic inflexibility are not evident, a possible candidate is carnitine 
palmitoyltransferase 1B (CPT1B), which is a rate-limiting step in FAO.  The present study was 
undertaken to determine if the differential response to lipid oversupply of the CPT1B gene in 
skeletal muscle with severe obesity is linked to epigenetic modifications (ie. DNA methylation 
and histone acetylation) that impact transcriptional activation.  In primary human skeletal muscle 
cultures the expression of CPT1B was blunted in severely obese women compared to their lean 
counterparts in response to lipid oversupply, which was accompanied by changes in CpG 
methylation, H3/H4 histone acetylation, and PPARδ and hepatocyte nuclear factor 4α (HNF-4α) 
transcription factor binding to the CPT1B promoter.  Our findings shed new light on the 
epigenetic modifications that play important roles in the transcriptional upregulation of CPT1B 
in response to a physiologically relevant lipid mixture in human skeletal muscle, which is a 
major site of fatty acid catabolism.  In terms of identifying mechanisms that contribute to the 
metabolic inflexibility with severe obesity, it is likely that differential DNA methylation partially 
explains the depressed expression of CPT1B among the obese women in response to lipid 
oversupply.  
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INTRODUCTION 
Mounting evidence indicates that metabolic diseases (i.e. obesity, type 2 diabetes, insulin 
resistance) are associated with an inability to oxidize lipids (1) and adjust substrate oxidation 
according to nutrient availability, termed ‘metabolic flexibility’ (2).  These impairments are 
particularly evident in the severely obese (Class III; BMI > 40kg/m
2
) where there is an impaired 
ability to oxidize lipid (fatty acid oxidation, FAO) in skeletal muscle and an inability to increase 
skeletal muscle FAO in response to a 3-5d high-fat diet (3, 4).  These decrements likely 
contribute to intramuscular lipid accumulation associated with insulin resistance, weight gain (5), 
and weight regain after weight loss (6).  
The molecular mechanisms contributing to this inability to oxidize lipid with severe 
obesity, however, are not evident.  A possible candidate is carnitine palmitoyltransferase (CPT1), 
which mediates the transfer of long chain fatty acids across the outer mitochondrial membrane 
and is a rate-limiting step in FAO (7).  The activity of the muscle-type CPT1 (encoded by the 
CPT1B gene) is reduced in skeletal muscle with obesity, contributing to a decrease in FAO (4). 
In relation to metabolic flexibility, in the skeletal muscle of lean subjects a high-fat diet 
increased the expression of CTP1B and the peroxisome proliferator-activated receptors (PPARs) 
which are upstream regulators of CPT1B expression (8).  Conversely, a high-fat diet resulted in 
little to no change in the expression of these genes in the skeletal muscle of severely obese 
subjects (8).  These data indicate a differential response to lipid oversupply with obesity which 
could contribute to positive lipid balance and ectopic lipid accumulation.   
Acute epigenetic modifications of the genome, such as DNA methylation and histone 
acetylation, may provide a connection between nutritional factors, gene expression, and 
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metabolic health.  Histone acetylation affects both chromatin structure as well as the interaction 
of transcription-regulatory proteins with target DNA in chromatin (9).  For example, an increase 
in the acetyl groups on histones will result in an open chromatin structure to facilitate 
accessibility of transcriptional machinery to DNA templates in chromatin, in turn increasing the 
expression of a gene.  Conversely, histone deacetylation may induce other epigenetic 
modifications (i.e. DNA methylation) leading to a decrease in gene expression.  There is a large 
body of evidence on the functional significance of both histone acetylation and DNA 
methylation levels and their correlation with gene expression as well as their importance in 
integrating environmental stimuli, such as diet, in the control of gene expression (9, 10).  
CPT1B is the predominant CPT1 isoform expressed in skeletal muscle (7).  While CPT1B 
plays an important role in human skeletal muscle lipid metabolism and has been shown to be 
differentially regulated in the skeletal muscle of severely obese individuals in response to a high-
fat diet (8), the transcriptional regulation of this gene in response to lipid oversupply has not 
been extensively examined.  The purpose of the present study was to determine if the differential 
response to lipid oversupply of the CPT1B gene in skeletal muscle with severe obesity is linked 
to epigenetic modifications (i.e. DNA methylation and histone acetylation) that impact 
transcriptional activation.  To our knowledge this is the first study to examine the transcriptional 
regulation of CPT1B in response to a physiologically relevant lipid oversupply, in terms of 
concentration and ratios of saturated to unsaturated fatty acids, in primary human skeletal muscle 
cell cultures (HSkMC).  By utilizing HSkMC we were able to study the molecular adaptations to 
a lipid stimulus in an environment void of in-vivo hormonal and neural stimuli and thus intrinsic 
to skeletal muscle itself. 
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EXPERIMENTAL PROCEDURES 
Study Design 
Briefly, the design of the study was to compare the mRNA response of the rate-limiting 
enzyme CPT1B to lipid oversupply in lean vs. severely obese subjects.  Skeletal muscle was 
obtained from the vastus lateralis and used to derive primary human skeletal muscle cell cultures 
(HSkMC).  After differentiation into myotubes, HSkMC were incubated in a physiologically 
relevant lipid mixture (250µM oleate:palmitate) for 48hr and mRNA content, DNA methylation, 
histone acetylation, and transcription factor binding to the CPT1B promoter region were 
determined. 
Materials 
All chemical reagents and substrates were purchased from Sigma (St. Louis, MO, USA) 
unless otherwise stated. Dulbecco’s Phosphate-Buffered Saline (DPBS), fetal bovine serum, 
heat-inactivated horse serum, gentamicin, 0.05% trypsin EDTA, and Hanks’s balanced salt 
solution were obtained from Invitrogen.  Growth media and differentiation media consisted of 
low glucose (5 mmol/L) Dulbecco’s Modified Eagles Medium from Invitrogen.  Type I collagen-
coated tissue culture plates were obtained from Becton Dickinson (Franklin Lakes, NJ, USA). 
PCR reagents were purchased from Applied Biosystems (Foster City, CA, USA).  
Human Subjects 
Muscle biopsies were obtained using the percutaneous needle biopsy technique (11) 
under local anesthesia (0.01% lidocaine) from the vastus lateralis of 9 lean (BMI= 22.8 kg/m
2
 
±0.7; Age= 23.4yrs ±1.5) and 9 severely obese (BMI= 41.3 kg/m
2
 ±1.5; Age= 29.9yrs±2.9) 
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Caucasian women.  Characteristics are presented in Table 1.  Participants were relatively young, 
free from disease, nonsmokers and not taking medications known to alter metabolism.  All 
procedures were approved by the East Carolina University Institutional Board.  
Primary HSkMC 
Satellite cells were isolated from ~50-100mg of fresh muscle tissue and cultured into 
myoblasts as previously described  (12).  For experiments cells were sub-cultured into T-150 
flasks and 10cm dishes.  Upon reaching ~80-90% confluence, differentiation was induced by 
switching the growth media to low-serum differentiation media containing 2% heat-inactivated 
horse serum, 0.05 mg/ml fetuin, and 5 µg/ml gentamicin.  On day 5 of differentiation, myotubes 
were given fresh differentiation media supplemented with 1) 0.1% bovine serum albumin (BSA) 
+ 1mM carnitine (CONTROL) or 2) 250µM oleate:palmitate (1:1 ratio) bound to 0.1% BSA + 
1mM carnitine (LIPID) for a total incubation period of 48 hours.  Myotubes were harvested on 
day seven similar to previous work (13).  There were no obvious differences in the extent of 
myotube morphology or differentiation between lean and obese HSkMC.  
RNA Isolation and mRNA quantification 
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia, CA) with on-
column DNase digestion using the RNase-Free DNase Set (Qiagen, Valencia, CA) to remove 
residual DNA.  RNA was quantified using the NanoDrop 1000 Spectrophotometer Version 3.7.1 
from Thermoscientific (Wilmington, DE, USA) and concentration was determined by measuring 
the absorbance at 260nm.  2ug of RNA was reverse transcribed into cDNA using the High 
Capacity cDNA Reverse Transcription Kit from Applied Biosystems (Foster City, CA, USA).  
PCR was performed in triplicate using the Applied Biosystems ABI 7900HT sequence detection 
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instrument and software with Taqman Universal PCR Master Mix and TaqMan gene expression 
assays (Applied Biosystems, Foster City, California) in accordance with manufacturer’s 
instructions.  Using standard techniques, reactions were run with the following thermal cycling 
conditions: 50˚C for 2 min; 95˚C for 10 min; and 40 cycles of 95˚C for 15 s; followed by 60˚C 
for 1 min.  mRNA content was measured using the comparative Ct method with a multiplexed 
endogenous control (18S) and converted to a linear function by using a base 2 antilog 
transformation.  
DNA Isolation  
Cells were washed with DPBS and trypsinized with trypsin-EDTA (0.05% trypsin and 
0.25% EDTA).  Total DNA (mitochondrial and nuclea) was extracted from cells using a 
QIAamp DNA mini kit (Qiagen, Valencia, CA) and total DNA quantified using the NanoDrop 
1000 Spectrophotometer Version 3.7.1 from Thermoscientific (Wilmington, DE, USA).  
Bisulfite Conversion and DNA Methylation Profiling  
500ng of DNA was used to perform bisulfate conversion using the EZ DNA Methylation 
Kit (Zymo Research, Orange, CA) following the manufacturer’s protocol, with the alternative 
incubation conditions recommended when using the Illumina Infunium Methylation Assay.  
Genome-wide DNA methylation analysis was conducted on bisulfate treated DNA samples using 
the Illumina Infinium HumanMethylation 450K BeadChip, which allows the quantitative 
monitoring of 485,764 cytosine positions (14).  12uL of each bisulfate-converted sample was 
amplified and fragmented, following the manufacturer’s protocol, hybridized to arrays in a 
balanced design and scanned on an Illumina iScan System. Data were output and analyzed using 
Illumina’s Genome Studio software. 
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Chromatin Immunoprecipitation (ChIP) Assay  
Cellular chromatin was cross-linked by adding 1% formaldyhyde.  The cross-linking 
reaction was stopped by adding 0.125M glycine and cells were then scrapped from the cell 
culture dishes, washed with PBS, centrifuged, and resuspended in lysis buffer (5mM Pipes [pH 
8.0], 85mM KCl, 0.4% NP40, Complete Mini EDTA-free protease inhibitor cocktail tablet 
[Roche, Branchburg, NJ]).  Pelleted nuclei were resuspended in a sonication solution (50mM 
Tris-HCl [pH 8.1], 1% SDS, 10mM EDTA, Complete Mini protease inhibitor cocktail tablet 
[Roche, Branchburg, NJ]) and sheared by sonication to an average size of 1 kb.  The sonicated 
chromatin was centrifuged and resuspended in IP buffer (16.7 mM Tris-HCl [pH 7.9], 167 mM 
NaCl, 0.01% SDS, 1.1% Triton-X, 1.2 mM EDTA, Complete Mini protease inhibitor cocktail 
tablet [Roche, Branchburg, NJ]).  An aliquot of each sample was removed as “input” and used in 
PCR analysis.  The soluble chromatin was incubated overnight at 4˚C in a rotating shaker with 
the following antibodies: 1) anti-PPAR alpha monoclonal (ab2779, Abcam, Cambridge, MA), 2) 
anti-PPAR delta polyclonal (ab125290, Abcam, Cambridge, MA), 3) anti-HNF-4 alpha 
monoclonal (ab41898, Abcam, Cambridge, MA), or 4) anti-acetyl-Histone H3 polyclonal (#06-
599, Millipore, Billerica, MA) and anti-acetyl-Histone H4 polyclonal (#06-866, Millipore, 
Billerica, MA).  Normal Rabbit IgG polyclonal antibody (#2729, Cell Signaling, Danvers, MA) 
was used as control for the ChIP assays.   Immune complexes were isolated by incubation with 
60 μl of ChIP-Grade Protein G Agarose Beads (Cell Signaling, Danvers, MA) for 1hr at 4°C.  
The complexes were serially washed in 1 ml low salt buffer (0.1% SDS, 1% Triton X-100, 0.2 M 
EDTA, 20 mM Tris-HCl [pH 8.1], 20% glycerol, 0.5 mM DTT, 100 mM NaCl) (twice), 1 ml of 
the same buffer but with high salt (500 mM NaCl) (twice), 1 ml of LiCl buffer (250 mM LiCl, 
1% NP-40, 100 mM NaCl, 1 mM EDTA, 10 mM Tris-HCl [pH 8.0]) (twice), and four times with 
 48 
 
TE (10 mM Tris-HCl [pH 7.5] and 1 mM EDTA).  The complexes were eluted with two 250μl 
aliquots of elution buffer (1% SDS and 0.1 M NaHCO3) at RT for 15min.  The cross-linking was 
reversed by adding 200mM NaCl and incubated at 56˚C overnight then subsequently  digested 
with 4ul RNase A (100 mg/ml)(Qiagen, Germantown, MD)  and 2ul of proteinase K (10mg/ml) 
at 45˚C for 1hr.  After reversing the cross-linking, DNA was isolated using the QIAquick PCR 
Purification Kit (Qiagen, Germantown, MD) according to the manufacturer’s instructions.  The 
input and bound DNA fractions were subjected to PCR and analyzed by with specified primer 
pairs.  The following primer set was used to assess HNF-4α binding and H3/H4 lysine 
acetylation in the CPT1B promoter region: 5’ primer 5-GGAACCTGACACCTACTCCC-3’ and 
the 3’ primer 5- ACATCGGTGACCTTTTCCCT-3’.  PPARα and PPARδ binding to the CPT1B 
promoter region was assessed using the EpiTect ChIP qPCR primer assay GPH1022780(-)01A 
(Qiagen, Germantown, MD).   
Statistical analysis 
Statistical analyses were performed using PASW Statistics 19 Software (SPSS Inc., 
Chicago, IL, USA) on raw or log-transformed data.  Comparisons between HSkMC from lean 
and obese donors were performed using independent samples t-tests.  All data met assumptions 
of sphericity and homogeneity of variance.  Data are presented as the mean ± SEM. 
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RESULTS 
Participant Characteristics 
Participant characteristics are presented in Table 3.1.  By design, the obese subjects were 
heavier and most had a body mass index (BMI) classified as Class III (severe) obesity (≥40 
kg/m
2
) (P<0.05).  Fasting blood glucose, cholesterol, and triglyceride values did not differ 
between groups.  However fasting HDL values were significantly lower, while insulin and 
homeostatic model assessment values were significantly higher in the obese subjects (P<0.05).  
Both groups consisted of relatively young individuals, and were age- and race-matched. 
Lipid Oversupply Increases CPT1B Gene Expression 
In response to the 48h 1:1 oleate:palmitate lipid treatment, there was a significant 
(P<0.001) increase in CPT1B mRNA content in both groups (Fig. 3.1); however, in the lipid-
treated condition CPT1B mRNA content was significantly lower (P<0.05) in the obese 
individuals compared to the lean (Fig. 3.1).  Under the control condition (i.e. pre-lipid exposure), 
there were no differences between the groups in CPT1B mRNA. 
Lipid Oversupply Remodels DNA Methylation 
DNA methylation was determined among 18 cytosines within the CPT1B gene (Fig. 
3.2A), 16 of which are located within 1000 base pairs (bp) of the transcription start site (TSS).  
There were no significant differences in basal methylation between the lean and obese 
individuals. However, in response to the lipid oversupply, there were significant (P<0.05) lipid-
treatment effects for cytosines at positions 3, 4, 7, 8, 12, 13, and 14 (-299, -295, -152, -134, 
+211, +223, and +229bp relative to the TSS) where methylation was lower in the lipid-treated 
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state relative to control.  Among the lean individuals (Fig. 3.2B), lipid oversupply resulted in a 
significant decrease in the methylation of six cytosines at positions 3, 4, 7, 8, 9, and 13 (-299, -
295, -152, -134, -83, and +223bp relative to the TSS) and a decrease in methylation of the 
cytosine at position 14 (+229bp relative to the TSS) which approached significance (P=0.10).  In 
addition, there was a significant increase in methylation at position 2 (-565bp from TSS) and a 
trend for an increase in methylation at cytosines 17 and 18 (+1,496 and +4321bp from the TSS; 
P=0.10 and P=0.06) in response to lipid oversupply among the lean women.  Among the obese 
women (Fig. 3.2C), lipid oversupply resulted in a significant decrease in the methylation of 
cytosines at positions 2, 4, 6, and 14 (-565, -295, -200, and +229bp relative to the TSS) and a 
trend for a decrease in the cytosine at position 13 (+223bp relative to the TSS; P=0.06).  There 
were no significant increases in methylation at any of the cytosines measured among the obese 
subjects in response to lipid oversupply.  
In terms of CPT1B exhibiting differential responses to lipid oversupply with obesity, the 
change in methylation of the cytosine at position 7 was significantly (P=0.05) different between 
groups (lean -12.3±4.6% vs. obese -1.5±1.9%) while the change in methylation of the cytosine at 
position 8 approached significance (lean -8.8±3.5% vs. obese -1.6±1.0%; P=0.07).  Additionally, 
there were significant interactions for cytosines at positions 2 and 6 (-565 and -200bp relative to 
the TSS) where methylation significantly decreased in the lipid-treated state in HSkMC from the 
obese, but not the lean subjects.  In fact, the lipid-induced change in methylation of the cytosine 
at position 6 was positively related to the lipid-induced relative change in CPT1B gene 
expression (r=0.71; P<0.01) (Fig. 3.3A).  Similarly, the methylation of cytosine 6 in the lipid-
treated condition was positively related with the mRNA content of CPT1B in the lipid-treated 
condition (r=0.52; P=0.03) (Fig. 3.3B).  
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Lipid Oversupply Increases Histone Acetylation and Transcription Factor Binding  
In searching for transcriptional regulators of CPT1B gene expression in response to lipid 
oversupply, we focused on promoter associated histone acetylation and transcription factor 
binding.  Overall, in response to the lipid oversupply, there were significant (P<0.05) increases 
in H3/H4 lysine acetylation (Fig. 3.4A) as well as increased HNF-4α (Fig. 3.4B) and PPARδ 
(Fig. 3.4D) transcription factor binding to the promoter region of CPT1B as assessed by 
chromatin immunoprecipitation (ChIP) assay.  There was a significant correlation between the 
relative change in histone acetylation and the relative changes in PPARδ (Fig. 3.5B) and HNF4-α 
(Fig. 3.5C) binding to the CPT1B promoter region.  Lipid oversupply failed to significantly 
increase PPARα transcription factor binding to the CPT1B promoter region (Fig. 3.4C) and there 
was no correlation between the relative change in histone acetylation and the relative change in 
PPARα (Fig. 3.5C) binding to the CPT1B promoter region.  There were no significant 
differences between lean and obese in terms of CPT1B promoter associated histone acetylations 
and transcription factor binding at baseline or in response to lipid oversupply. 
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DISCUSSION 
In lean individuals, whole-body lipid oxidation increases in response to a high-fat diet, 
however with obesity, there is an impairment in the ability to adjust to lipid exposure in a similar 
manner (3, 15).  The goal of the present study was to determine if the expression of a rate-
limiting enzyme in skeletal muscle mitochondrial FAO, CPT1B, differed in a manner indicative 
of a lack of metabolic flexibility with obesity and if the transcriptional regulation of CPT1B 
could be explained by epigenetic modifications.  The main findings of the current study were 
that: 1) the expression of CPT1B was blunted in the severely obese women compared to their 
lean counterparts in response to lipid oversupply and 2) that changes in CpG methylation, H3/H4 
histone acetylation, and transcription factor binding accompanied this response suggesting that 
CPT1B is, at least in part, regulated by epigenetic modifications in human skeletal muscle.  
  CPT1 exists as three isoforms encoded by separate genes: liver-type (encoded by 
CPT1A), muscle-type (encoded by CPT1B), and brain-type (encoded by CPT1C).  The CPT1B 
gene consists of ~11kb and contains 19 introns and 19 exons, the first of which is non-coding 
and alternatively transcribed into either: 1) exon 1A (also called U) that is expressed ubiquitously 
or 2) exon 1B (also called M) that is expressed abundantly in heart and skeletal muscle (16, 17).   
Long chain fatty acids can regulate CPT1B gene expression (16, 18) via PPARα activation and 
subsequent binding to the peroxisome proliferator response element (PPRE) within the CPT1B 
promoter region (16, 19).  Data from Muoio et al. indicates that PPARα and PPARδ play 
redundant roles in the activation of CPT1B gene expression in skeletal muscle (20), while other 
data suggests that CPT1B is preferentially regulated by PPARδ, and not PPARα in skeletal 
muscle (21).  Our findings also suggest that PPARδ may play a more important role in the 
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transcriptional activation of CPT1B compared to PPARα, in response to lipid exposure as we 
observed a significant increase in PPARδ binding to the CPT1B promoter region, but failed to 
see an increase in PPARα binding (Fig. 3.4). 
HNF-4α is a nuclear transcription factor that regulates the expression of several genes 
involved with energy metabolism and other nuclear receptors, including the PPARs, and HNF-4α 
mutations have been associated with metabolic diseases such as type 2 diabetes and 
hyperlipidemia (22).  The proposed mechanisms by which HNF-4α exerts transcriptional 
regulation include chromatin structure modulation via histone acetyltransferase recruitment as 
well as interactions with other transcription factors such as HNF-1, HNF-6, GATA 4, GATA6, 
p21, PGC-1α and SREBP2 (23).  It has been suggested that the transcriptional regulation of some 
genes involved with lipid metabolism (ie. ACOT, ACOX, CD36, CPT, and ThB) relies on 
interactions between the PPARs and HNF-4α (23).  For example, Martinez-Jimenez et al. 
reported that fasting-mediated transcriptional activation of CPT1 required the synergism of 
HNF-4α and PPARα (24). While our findings do not definitely show that the lipid-induced 
transcriptional regulation of CPT1B requires the synergism of HNF4α and PPARδ, our data 
supports a recently described model of CPT1B transcriptional regulation proposed by 
Chamouton and Latruffe (23) where HNF-4α, bound to the PPRE, recruits a ligand-activated 
PPAR to the promoter in response to altered substrate availability, suggesting that these two 
receptors act in a crosstalk manner.  Additionally, both HNF4-α and PPARδ binding to the 
CPT1B promoter were positively correlated with increased histone acetylation (Fig. 3.5) in 
response to lipid oversupply which is consistent with the concept that histone acetylation opens 
the chromatin structure to facilitate accessibility of transcriptional machinery to the promoter 
regions of genes, thereby regulating activation.  
 54 
 
DNA methylation is considered to be a major regulator of transcriptional activity where 
increased DNA methylation inhibits promoter activity by directly impeding the binding of 
transcriptional factors to their target sites, consequently reducing gene expression (10).  In 
response to lipid oversupply, there was a significant (P<0.05) increase in CPT1B mRNA content 
(Fig. 3.1), which was accompanied by significant decreases in methylation among seven out of 
eighteen cytosines measured.  Among the obese women only two of the seven cytosines 
exhibited a lipid-induced decrease in methylation, compared to five out of seven among the lean 
women (Fig. 3.2).  This suggests the overall lipid-induced decrease in methylation was driven by 
the lean individuals, which is in agreement with CPT1B mRNA content being significantly 
higher in muscle cells derived from lean compared to obese subjects (Fig. 3.1).  In addition, the 
overall extent to which methylation changed in response to lipid oversupply tended to be lower 
in the obese subjects (Fig. 3.2), which is in accordance with individuals at a greater risk of 
developing metabolic disease tending to have a lower sensitivity to environmental challenges (ie. 
high-fat feeding) and acutely regulating DNA methylation (25).  
While fatty acids have been shown to increase the transcription of genes that play roles in 
the oxidation of lipids, glucose can induce the transcriptional response of glycolytic and 
lipogenic enzymes (26).  One transcription factor that has been implicated in the carbohydrate-
mediated regulation of glycolytic and lipogeneic genes is upstream stimulatory factor (USF) 
(27).  USFs are members of the basic-helix-loop-helix leucine zipper family of transcription 
factors, are ubiquitously expressed, and have been implicated in several metabolic diseases (26-
29).  Using MATCH
TM
 public version 1.0, which is a matrix search for transcription factor 
binding sites based on TRANSFAC® (30), we identified potential USF binding sites within the 
CPT1B promoter based on sequence analysis and identified two USF binding sites which 
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contained cytosines at positions 2 and 6.  Interestingly, of the cytosines measured in this analysis, 
these were the only two that showed a significant (P<0.05) interaction effect where methylation 
significantly decreased in the lipid-treated state in HSkMC from the obese, but not the lean 
subjects. In fact, methylation of the cytosine at position 2 significantly increased among the lean 
women in response to lipid treatment (Fig. 2), which would suggest a reduction in transcription 
factor binding at this site.  Additionally, the relative change in methylation of the cytosine at 
position 6 was positively related to the relative change in CPT1B mRNA content in response to 
lipid oversupply (Fig. 3.3).  USF has not been previously implicated in the regulation of CPT1B 
in response to lipid treatment.  However, data from Putt et al. uncovered a molecular relationship 
between several metabolic genes and USF in response to nutrient challenges, including a high-fat 
meal, and suggested that this relationship played a role in the transcriptional fine tuning of these 
metabolic genes (29).  Additionally, it has been suggested that USF may play a role in 
maintaining the chromatin structure environment at promoter sites and, similar to the PPARs, 
may switch from activator to repressor depending on which signal transduction pathways are 
operating (27).  While purely speculative at this point, the significant decrease in methylation at 
two possible USF binding sites among the obese women with lipid supports the notion that USF 
binding could be acting as a repressor and a partial brake on the lipid-induced upregulation of 
CPT1B.  This mechanism may, in part, explain the significantly reduced expression of CPT1B 
mRNA content in response to lipid treatment in skeletal muscle cells derived from obese women 
(Fig. 3.1).  
In summary, by utilizing primary human skeletal muscle cell cultures (HSkMC) we were 
able to study the transcriptional regulation of CPT1B in response to a lipid stimulus in the 
skeletal muscle of lean and severely obese humans.  Our findings indicate a dampened CPT1B 
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response to lipid, which likely contributes to the metabolic inflexibility evident in skeletal 
muscle with severe obesity.  A novel finding was that epigenetic modifications, including histone 
acetylation and DNA methylation, both of which were associated with transcription factor 
binding, play an important role in the transcriptional upregulation of CPT1B in response to a 
physiologically relevant lipid mixture (31) in humans and it is likely that differential DNA 
methylation partially explains the depressed expression of CPT1B among the severely obese 
women.   
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TABLES AND FIGURES 
Table 3.1 Subject Characteristics 
 Lean (n=12) Obese (n=10) 
Age (y) 23.4±1.5 29.9±2.9 
Stature (cm) 164.7±1.8 165.5±2.2 
Mass (kg) 62.6±1.3 113.7±6.3* 
BMI (kg/m
2
) 22.8±0.7 41.3±1.5* 
Fasting glucose (mmol/L) 4.6±0.1 4.9±0.4 
Fasting insulin (uU/L) 4.3±1.2 18.3±5.8* 
HOMA-IR 0.9±0.3 3.2±1.0* 
Plasma cholesterol (mg/dl) 179±8 169±11 
Plasma triglycerides (mg/dl) 102±7 105±16 
HDL (mg/dl) 56±4 40±4* 
 
Results are expressed as mean±SEM 
*Significantly different (P < 0.05) from lean. 
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Fig. 3.1 Effect of lipid oversupply (48hr 250µM oleate:palmitate treatment) on mRNA content 
of CPT1B in cultured myotubes (HSkMC) from lean (open bars) and severely obese (solid bars) 
donors. Data are expressed as mean±SEM. *, Significant difference (P≤0.05) between lean and 
obese individuals. Φ, Significant difference (P≤0.01) between control and lipid-treated. 
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Fig. 3.2 CPT1B gene methylation. Visualization of the 18 measured CpG sites within the CPT1B 
gene (A). DNA methylation changes in response to lipid oversupply (methylation value in the 
lipid-treated condition minus the baseline methylation value) at each of the 18 measured 
cytosines among the lean individuals (B) and the severely obese individuals (C). *, Significant 
difference (P≤0.05) between the baseline and lipid-treated condition. #, Difference between 
baseline and lipid-treated condition approached significance (P≤0.1). TSS is indicated by the 
arrow. 
A 
 
 
 
 
 
 
 
 64 
 
B 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
 
 
Lean
M
e
th
y
la
ti
o
n
 C
h
a
n
g
e
 (
%
 p
o
in
t)
-20
-10
0
10
20
*
*
*
*
*
*
*
#
#
#
1      2     3      4     5      6      7      8     9    10    11    12    13   14    15    16    17    18
Obese
M
e
th
y
la
ti
o
n
 C
h
a
n
g
e
 (
%
 p
o
in
t)
-20
-10
0
10
20
* *
*
*
#
1      2     3      4     5      6      7      8     9    10    11    12    13   14    15    16    17    18
 65 
 
Fig. 3.3 The association of CPT1B methylation and CPT1B mRNA content. The change in 
methylation in response to lipid oversupply (methylation value in the lipid-treated condition 
minus the baseline methylation value) of the cytosine at position 6 was positively related to the 
relative change in CPT1B mRNA content (lipid-treated divided by baseline) (A). Methylation of 
the cytosine at position 6 in the lipid-treated condition was positively related to CPT1B mRNA 
content in the lipid-treated condition (B).    
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Fig. 3.4 Effect of lipid oversupply (48hr 250µM oleate:palmitate treatment) on CPT1B promoter 
associated  changes in H3/H4 histone acetylation (A) and HNF-4α (B), PPARα (C), and PPARδ 
(D) transcription factor binding in cultured myotubes (HSkMC) from lean (open bars) and 
severely obese (solid bars) donors. Data are expressed as mean±SEM. Φ, Significant difference 
(P≤0.05) between control and lipid-treated. 
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Fig. 3.5 The association of CPT1B promoter region H3/H4 histone acetylation and transcription 
factor binding to the CPT1B promoter region. The relative change (lipid-treated divided by 
baseline) in PPARα (A), PPARδ (B), and HNF-4α (C) transcription factor binding to the CPT1B 
promoter region in response to lipid oversupply was related to the relative change (lipid-treated 
divided by baseline) in H3/H4 histone acetylation of the CPT1B promoter region.  
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CHAPTER 4: SUMMARY OF FINDINGS 
With obesity, there are impairments in the ability to adjust substrate utilization to changes 
in substrate availability, referred to as metabolic inflexibility (1-3).  In respect to lipid 
metabolism, we reported that obese individuals lacked the ability to increase fat oxidation with 
either a high fat diet (4) or in HSkMC upon lipid incubation (5).  This dissertation examined if 
the expression of genes linked with FAO and mitochondrial content also differed in a manner 
indicative of a lack of metabolic flexibility with severe obesity and to what extent the differential 
responses to lipid oversupply were linked with the chromatin environment and/or the 
methylation signature of these genes.  The main findings were that: 1) the increased expression 
of genes that act as vital transcriptional and enzymatic regulators of FAO and mitochondrial 
content were blunted in the severely obese women compared to their lean counterparts in 
response to lipid oversupply and 2) that changes in CpG methylation, H3/H4 histone acetylation, 
and transcription factor binding were evident in this lipid-induced response suggesting that some 
genes (ie. CPT1B and PPARδ) are, at least in part, regulated by epigenetic modifications in 
human skeletal muscle.  These data provide the novel information that with severe obesity the 
metabolic inflexibility evident with lipid exposure may be linked with an inability to upregulate 
some transcriptional regulators via epigenetic modifications.   
The first study in this dissertation focused on the peroxisome proliferator-activated 
receptors (PPARs) and nuclear respiratory factors (NRFs) , which are provocative candidates for 
explaining the metabolic inflexibility in response to lipid oversupply with obesity as they 
activate gene expression programs critical to mitochondrial function and FAO (6-9).  The NRFs 
are essential for the expression several genes that are critical to FAO including genes that encode 
subunits of the five respiratory complexes of the mitochondrial inner membrane, genes which 
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direct the expression and assembly of the respiratory apparatus, and genes which function in 
mitochondrial protein import and initiate mtDNA transcription and replication (10, 11).  NRF-1, 
and NRF-2, exhibited patterns of increasing mRNA content with lipid exposure in the lean, but 
not in HSkMC from the severely obese (Fig. 2.1).  Of the six NRF-regulated genes examined, 
cytochrome c (CYCS) exhibited a similar pattern of increasing mRNA content with lipid 
oversupply in the lean, but decreasing with obesity (Fig. 2.3).  We cannot discount the possibility 
that these findings may have been influenced by the time we chose to obtain the samples, i.e. that 
similar or more divergent mRNA responses in lean and obese subjects could have occurred at 
earlier or later time points during lipid incubation. 
The PPARs are ligand-activated transcription factors that play essential roles in lipid 
homeostasis by modulating the expression of genes that regulate fatty acid catabolism.  There are 
three PPAR subtypes: 1) PPARα, which mediates lipid-induced activation of FAO genes and is 
expressed predominately in tissues that are characterized by high rates of FAO (ie. liver, heart, 
muscle, kidney); 2) PPARγ, which is highly enriched in adipocytes and macrophages and is 
involved in adipocyte differentiation, lipid storage, and glucose homeostasis; and 3) PPARδ, 
which is ubiquitously expressed and has the least defined function, but has recently been 
characterized as being highly expressed in skeletal muscle and playing a lipid-metabolizing role 
similar to PPARα (7, 8, 12).  Their critical role in energy homeostasis is supported by the 
observation that PPARα knockout mice exhibit a dramatic inhibition of fatty acid uptake and 
oxidation, abnormal accumulation of lipids in oxidative tissues, and a failure to induce beta-
oxidation in response to physiological challenges such as a high-fat diet (13).  In the first study, 
the mRNA content of PPARα and PPARδ increased with lipid exposure in the lean, but 
decreased in HSkMC from the severely obese (Fig. 2.1 and 2.2).  Additionally, several PPAR-
 71 
 
responsive genes including citrate synthase (CS), mitochondrial uncoupling protein 3 (UCP3), 
and pyruvate dehydrogenase kinase 4 (PDK4) showed trends for being upregulated more 
robustly in HSkMC from lean but not obese subjects (Fig. 2.3).  
Of the PPAR-responsive genes that were differentially regulated by the 48hr lipid 
oversupply PDK4 is of particular interest as it suppresses glucose and promotes fat oxidation in 
the presence of lipids (14).  We have previously shown that a high fat diet increased PDK4 
mRNA content in lean, but not obese individuals (15); in the current study utilizing HSkMC, the 
lipid-induced increase in PDK4 mRNA content in the lean was more than 2-fold greater than the 
response in the obese (42.0±8.1 vs. 20.4±3.8 fold increase) (Fig. 2.3).  This data is consistent 
with an inability to switch from predominately glucose oxidation to FAO in the presence of a 
lipid challenge with obesity.  
In the second study of this dissertation, the response to another PPAR-responsive gene, 
the muscle-type carnitine palmitoyltransferase 1B (CPT1B), was evaluated. CPT1 mediates the 
transfer of long chain fatty acids across the outer mitochondrial membrane which is a rate-
limiting step in FAO (16).  The activity of the muscle-type CPT1 (encoded by the CPT1B gene) 
is reduced in skeletal muscle with obesity, contributing to a decrease in FAO (17).  In relation to 
metabolic flexibility, in the skeletal muscle of lean subjects a high fat diet increased the 
expression of CTP1B and the peroxisome proliferator-activated receptors (PPARs) which are 
upstream regulators of CPT1B expression (15).  Conversely, a high fat diet resulted in little to no 
change in the expression of these genes in the skeletal muscle of severely obese subjects (15).   
Our data showed that in response to lipid treatment, there was a significant increase in CPT1B 
mRNA content in both groups (Fig. 3.1); however, in the lipid-treated condition CPT1B mRNA 
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content was significantly lower in the obese individuals compared to the lean (Fig. 3.1).  Our 
findings indicate a dampened CPT1B response to lipid which likely contributes to the metabolic 
inflexibility evident in skeletal muscle with severe obesity.  
Taken together, our findings indicate a coordinated activation of genes linked with FAO 
and mitochondrial content among lean individuals in response to lipid oversupply that is largely 
absent with obesity.  In addition to our examination of the differential lipid-induced upregulation 
of genes linked with FAO and mitochondrial content among lean and obese women, we 
examined to what extent the differential responses to lipid oversupply were linked with the 
chromatin environment and/or the methylation signature of these genes.  Epigenetic 
modifications of the genome, including DNA methylation and histone acetylation, may provide a 
connection between nutritional factors, gene expression, and metabolic health.  
DNA methylation is considered to be a major regulator of transcriptional activity and 
may provide a mechanism for the regulation of gene expression in response to lipid and/or could 
help explain the differential responses in gene expression in the skeletal muscle of lean vs. 
severely obese individuals.  Our data, along with others (18, 19), supports the growing awareness 
that DNA methylation can be viewed as a dynamic signal that is associated with changes in 
substrate availability, such as lipid oversupply.  However, the relationship of gene expression 
with DNA methylation, as well as the precise functional relevance of differential methylation is 
not straightforward.   For example, Jacobsen et al. (19) observed that, in response to a high-fat 
diet, relatively immediate changes in DNA methylation can be slow to reverse, but the functional 
relevance of this slow reversibility is not known (19).  The authors suggest that perhaps the 
methylation changes induced by the high-fat diet actually prevented potentially detrimental 
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effects of the high-fat diet on gene expression (19).  In our study, the overall extent to which 
methylation changed in response to lipid oversupply tended to be lower in the obese subjects in 
both studies (Fig. 2.4 and 3.2).  This finding is in accordance with previous work showing that 
individuals at a greater risk of developing metabolic disease tended to have a lower sensitivity to 
environmental challenges (ie. high-fat feeding) in terms of the ability to regulate changes in 
DNA methylation (20).  We did not assess the reversibility of changes in methylation, but future 
studies addressing the functional relevance of lingering changes in methylation could give us 
additional insight into the lipid-induced regulation of the genes examined in this dissertation.  
DNA methylation is generally accepted to regulate gene transcription by directly 
impeding the binding of transcriptional factors to their target sites and through the recruitment of 
methyl-binding proteins (21).  However, our findings indicated a positive relationship between 
the extent of PPARδ promoter methylation and PPARδ mRNA content in response to lipid 
oversupply (Fig. 2.6).  Additionally, the extent of methylation of one cytosine -200bp relative to 
the TSS in the CPT1B promoter region was positively related with the mRNA content of CPT1B 
in the lipid-treated condition (Fig. 3.3).  While purely speculative at this point, the divergent 
methylation signatures between the lean and obese women of cytosines in the promoter regions 
of CPT1B and PPARδ, that are positively correlated with mRNA content, supports the notion 
that methylation may be impeding the binding of an unknown repressor.  Future studies aimed at 
identifying these potential repressors could shed light on the regulation of these genes, which 
play vital roles in lipid metabolism, and could provide additional insight into mechanisms 
responsible for the metabolic inflexibility evident with severe obesity.  With this in mind, it is 
intriguing to imagine if, in the future, therapeutic modalities to treat obesity and/or metabolic 
inflexibility might include approaches to manipulate the methylation status of a single nucleotide 
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within the promoter region of a targeted gene, in an effort to modify promoter occupancy, in turn 
regulating the transcriptional activity of the gene.    
Another epigenetic modification, histone acetylation, also is considered to be a major 
regulator of transcriptional activity via modulation of chromatin structure which influences the 
interaction of transcription-regulatory proteins with target DNA in chromatin (22).  For example, 
an increase in the acetyl groups on histones will result in an open chromatin structure to facilitate 
accessibility of transcriptional machinery to DNA templates in chromatin, in turn increasing the 
expression of a gene.  Overall, in response to the lipid oversupply, there were significant 
increases among the lean and obese groups in H3/H4 lysine acetylation (Fig. 3.4) as well as 
increased HNF-4α (Fig. 3.4) and PPARδ (Fig. 3.4) transcription factor binding to the promoter 
region of CPT1B.  Additionally, both HNF4-α and PPARδ binding to the CPT1B promoter were 
positively correlated with histone acetylation (Fig. 3.5) in response to lipid oversupply which is 
consistent with the concept that increasing histone acetylation opens the chromatin structure to 
facilitate accessibility of transcriptional machinery to the promoter regions of genes, thereby 
regulating activation. 
HNF-4α is a nuclear transcription factor that regulates the expression of several genes 
involved with energy metabolism and other nuclear receptors, including the PPARs, and HNF-4α 
mutations have been associated with metabolic diseases such as Type II diabetes and 
hyperlipidemia (23).  The proposed mechanisms by which HNF-4α exerts transcriptional 
regulation include chromatin structure modulation via histone acetyltransferase recruitment as 
well as interactions with other transcription factors such as the PPARs (24).  For example, 
Martinez-Jimenez et al. reported that fasting-mediated transcriptional activation of CPT1 
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required the synergism of HNF-4α and PPARα (25).  Our findings did not definitely show that 
the lipid-induced transcriptional regulation of CPT1B requires the synergism of a PPAR and 
HNF4α, however our data supports a recently described model of CPT1B transcriptional 
regulation (24) where HNF-4α, bound to the Peroxisome Proliferator Response Element (PPRE), 
recruits a ligand-activated PPAR to the promoter in response to altered substrate availability.  
Our data suggests that PPARδ, not PPARα, is the ligand-activated PPAR recruited to the CPT1B 
promoter region in response to lipid oversupply, indicating that PPARδ may play a more 
important role in the lipid-induced transcriptional activation of CPT1B compared to PPARα.  
Together these data indicate that histone acetylation, which is associated with HNF-4α and 
PPARδ transcription factor binding, plays an important role in the transcriptional upregulation of 
CPT1B in response to a physiologically relevant lipid mixture (26) in humans.  
As mentioned previously, PPARδ has the least defined function of the three PPAR 
subtypes.  In light of this, it is particularly interesting that PPARδ was the only gene whose 
mRNA content was significantly lower in the obese individuals compared to the lean at baseline 
and in response to lipid oversupply (Fig. 2.2).  There was a significant interaction effect for 
PPARδ where mRNA content was elevated in the lipid-treated state in HSkMC from the lean, 
but decreased in HSkMC from the obese subjects (Fig. 2.2).  Additionally, PPARδ, not PPARα, 
binding to the CPT1B promoter region increased in response to lipid oversupply and was 
significantly correlated with CPT1B mRNA content in response to lipid exposure.  Together this 
data indicates that PPARδ may play a more important role in the transcriptional activation of 
CPT1B, and perhaps in skeletal muscle metabolic flexibility and lipid metabolism, than 
previously thought.  Not surprisingly, along with PPARα and PPARγ agonists, PPARδ agonists 
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are currently under assessment in clinical trials and seem to be promising drugs for the 
improvement of parameters associated with dyslipidemia, insulin resistance, and obesity (27).  
In summary, by utilizing primary human skeletal muscle cell cultures (HSkMC) we were 
able to study the transcriptional regulation of mitochondrial and lipid-oxidizing genes in 
response to a lipid stimulus in the skeletal muscle of lean and severely obese humans in an 
environment void of in-vivo hormonal and neural stimuli and thus intrinsic to skeletal muscle 
itself.  The purpose of the present study was to determine if the expression of genes linked with 
FAO and mitochondrial content differed in a manner indicative of a lack of metabolic flexibility 
with obesity and to what extent the differential responses to lipid oversupply were linked with 
the chromatin environment and/or the methylation signature of these genes.  The main findings 
were that: 1) the coordinated activation of genes linked with FAO and mitochondrial content 
among lean individuals in response to lipid oversupply is largely absent with obesity and 2) that 
changes in CpG methylation, increased histone acetylation, and transcription factor binding 
accompanied this response, suggesting that epigenetic modifications play a role in the lipid-
induced upregulation of these genes.  These data provide the novel information that with severe 
obesity the metabolic inflexibility evident in response to lipid exposure may be linked with an 
inability to upregulate transcriptional regulators caused by differential epigenetic modifications. 
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